nils-herrmann/clean_scirepeval huggingface dataset:
Doing the Difficult Stuff: Influence of Self Determined Motivation Toward the Environment on Transportation Proenvironmental Behavior

Past research has shown that as proenvironmental behaviors (PEBs) become more difficult, the level of self determined motivation becomes a more powerful predictor of behavior participation. The purpose of this study was to (1) examine the perceived difficulty of transportation PEB in two contexts using self determination theory and (2) examine the mediation effect of autonomous and controlled motivation toward the environment. Results indicate that when the transportation behavior was perceived as difficult to perform, autonomous motivation was associated with more frequent participation. When the transportation behavior was perceived to be easy, motivation type had no influence on behavior frequency. Mediation analysis indicated a significant total indirect effect of perceived environmental competence on frequency of easy PEB via both types of motivation, but for difficult behaviors only autonomous motivation was a significant mediator. This study suggests that increasing individuals' autonomous.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Venue: The New England journal of medicine

Daratumumab, a human IgGk monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.  In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of body surface area) and dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per kilogram of body weight) (daratumumab group) The primary end point was progression free survival.  A prespecified interim analysis showed that the rate of progression free survival was significantly higher in the daratumumab group than in the control group; the 12 month rate of progression free survival was 60.7% in the daratumumab group versus 26.9% in the control group. After a median follow up period of 7.4 months, the median progression free survival was not reached in the daratumumab group and was 7.2 months in the control group (hazard ratio for progression or death with daratumumab vs. control, 0.39; 95% confidence interval, 0.28 to 0.53; P<0.001) The rate of overall response was higher in the daratumumab group than in the control group (82.9% vs. 63.2% P<0.001) as were the rates of very good partial response or better (59.2% vs. 29.1% P<0.001) and complete response or better (19.2% vs. 9.0% P=0.001) Three of the most common grade 3 or 4 adverse events reported in the daratumumab group and the control group were thrombocytopenia (45.3% and 32.9% respectively) anemia (14.4% and 16.0% respectively) and neutropenia (12.8% and 4.2% respectively) Infusion related reactions that were associated with daratumumab treatment were reported in 45.3% of the patients in the daratumumab group; these reactions were mostly grade 1 or 2 (grade 3 in 8.6% of the patients) and in 98.2% of these patients, they occurred during the first infusion.  Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression free survival than bortezomib and dexamethasone alone and was associated with infusion related reactions and higher rates of thrombocytopenia and neutropenia than bortezomib and dexamethasone alone.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Venue: The New England journal of medicine

Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1 2 study involving patients with relapsed or refractory multiple myeloma.  In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group) The primary end point was progression free survival.  At a median follow up of 13.5 months in a protocol specified interim analysis, 169 events of disease progression or death were observed (in 53 of 286 patients [18.5% in the daratumumab group vs. 116 of 283 [41.0% in the control group; hazard ratio, 0.37; 95% confidence interval [CI] 0.27 to 0.52; P<0.001 by stratified log rank test) The Kaplan Meier rate of progression free survival at 12 months was 83.2% (95% CI, 78.3 to 87.2) in the daratumumab group, as compared with 60.1% (95% CI, 54.0 to 65.7) in the control group. A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4% P<0.001) as was a higher rate of complete response or better (43.1% vs. 19.2% P<0.001) In the daratumumab group, 22.4% of the patients had results below the threshold for minimal residual disease (1 tumor cell per 105 white cells) as compared with 4.6% of those in the control group (P<0.001) results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group) thrombocytopenia (in 12.7% vs. 13.5% and anemia (in 12.4% vs. 19.6% Daratumumab associated infusion related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2.  The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009
Daratumumab monotherapy in patients with treatment refractory multiple myeloma (SIRIUS) an open label, randomised, phase 2 trial
Venue: The Lancet

New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs. We assessed daratumumab, a novel CD38 targeted monoclonal antibody, in patients with refractory multiple myeloma.  In this open label, multicentre, phase 2 trial done in Canada, Spain, and the USA, patients (age =18 years) with multiple myeloma who were previously treated with at least three lines of therapy (including proteasome inhibitors and immunomodulatory drugs) or were refractory to both proteasome inhibitors and immunomodulatory drugs, were randomly allocated in a 1:1 ratio to receive intravenous daratumumab 8 mg/kg or 16 mg/kg in part 1 stage 1 of the study, to decide the dose for further assessment in part 2. Patients received 8 mg/kg every 4 weeks, or 16 mg/kg per week for 8 weeks (cycles 1 and 2) then every 2 weeks for 16 weeks (cycles 3 6) and then every 4 weeks thereafter (cycle 7 and higher) The allocation schedule was computer generated and randomisation, with permuted blocks, was done centrally with an interactive web response system. In part 1 stage 2 and part 2, patients received 16 mg/kg dosed as in part 1 stage 1. The primary endpoint was overall response rate (partial response [PR] very good PR complete response [CR] stringent CR) All patients who received at least one dose of daratumumab were included in the analysis.   The study is ongoing. In part 1 stage 1 of the study, 18 patients were randomly allocated to the 8 mg/kg group and 16 to the 16 mg/kg group. Findings are reported for the 106 patients who received daratumumab 16 mg/kg in parts 1 and 2. Patients received a median of five previous lines of therapy (range 2 14) 85 (80% patients had previously received autologous stem cell transplantation, 101 (95% were refractory to the most recent proteasome inhibitors and immunomodulatory drugs used, and 103 (97% were refractory to the last line of therapy. Overall responses were noted in 31 patients (29.2% 95% CI 20.8 38.9) three (2.8% 0.6 8.0) had a stringent CR, ten (9.4% 4.6 16.7) had a very good PR, and 18 (17.0% 10.4 25.5) had a PR. The median time to first response was 1.0 month (range 0.9 5.6) Median duration of response was 7.4 months (95% CI 5.5 not estimable) and progression free survival was 3.7 months (95% CI 2.8 4.6) The 12 month overall survival was 64.8% (95% CI 51.2 75.5) and, at a subsequent cutoff, median overall survival was 17.5 months (95% CI 13.7 not estimable) Daratumumab was well tolerated; fatigue (42 [40% patients) and anaemia (35 [33% of any grade were the most common adverse events. No drug related adverse events led to treatment discontinuation.  Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Venue: The New England journal of medicine

Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.  In this double blind, placebo controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide dexamethasone (ixazomib group) or placebo plus lenalidomide dexamethasone (placebo group) The primary end point was progression free survival.  Progression free survival was significantly longer in the ixazomib group than in the placebo group at a median follow up of 14.7 months (median progression free survival, 20.6 months vs. 14.7 months; hazard ratio for disease progression or death in the ixazomib group, 0.74; P=0.01) a benefit with respect to progression free survival was observed with the ixazomib regimen, as compared with the placebo regimen, in all prespecified patient subgroups, including in patients with high risk cytogenetic abnormalities. The overall rates of response were 78% in the ixazomib group and 72% in the placebo group, and the corresponding rates of complete response plus very good partial response were 48% and 39% The median time to response was 1.1 months in the ixazomib group and 1.9 months in the placebo group, and the corresponding median duration of response was 20.5 months and 15.0 months. At a median follow up of approximately 23 months, the median overall survival has not been reached in either study group, and follow up is ongoing. The rates of serious adverse events were similar in the two study groups (47% in the ixazomib group and 49% in the placebo group) as were the rates of death during the study period (4% and 6% respectively) adverse events of at least grade 3 severity occurred in 74% and 69% of the patients, respectively. Thrombocytopenia of grade 3 and grade 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, respectively) than in the placebo group (5% and 4% of the patients, respectively) Rash occurred more frequently in the ixazomib group than in the placebo group (36% vs. 23% of the patients) as did gastrointestinal adverse events, which were predominantly low grade. The incidence of peripheral neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 events occurred in 2% of the patients in each study group) Patient reported quality of life was similar in the two study groups.  The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression free survival; the additional toxic effects with this all oral regimen were limited.
Single shot laser pulse reconstruction based on self phase modulated spectra measurements
Venue: Scientific reports

We report a method for ultrashort pulse reconstruction based only on the pulse spectrum and two self phase modulated (SPM) spectra measured after pulse propagation through thin media with a Kerr nonlinearity. The advantage of this method is that it is a simple and very effective tool for characterization of complex signals. We have developed a new retrieval algorithm that was verified by reconstructing numerically generated fields, such as a complex electric field of double pulses and few cycle pulses with noises, pedestals and dips down to zero spectral intensity, which is challenging for commonly used techniques. We have also demonstrated a single shot implementation of the technique for the reconstruction of experimentally obtained pulses. This method can be used for high power laser systems operating in a single shot mode in the optical, near and mid IR spectral ranges. The method is robust, low cost, stable to noise, does not require a priori information, and has no ambiguity related to time direction.
The Long Term Pelvic Floor Health Outcomes of Women After Childbirth: The Influence of Labour in the First Pregnancy.
Venue: Journal of obstetrics and gynaecology Canada JOGC Journal d'obstetrique et gynecologie du Canada JOGC

To estimate the influence of labour and pregnancy factors on long term pelvic floor health outcomes.  This population based cohort study was conducted using linkage between the Nova Scotia Atlee Perinatal Database, the Medical Services Insurance Database, and the Canadian Institute for Health Information's Discharge Abstract Database from 1988 to 2006; this allowed for the evaluation of patient utilization of care providers for pelvic floor disorders and captured conservative and surgical interventions. We compared rates of urinary and anal incontinence, pelvic organ prolapse, and fistula disorders in women undergoing Caesarean section (CS) without labour and women undergoing labour with any method of delivery. Multivariate logistic regression and survival (time to event) analyses were performed.  Absolute risks for the selected pelvic floor health outcomes were low, regardless of whether labour was experienced in the first pregnancy. Women with one or more deliveries who had a CS without labour in their first pregnancy had reduced risks for all pelvic floor health outcomes, except fistula formation, and they were also less likely to develop these outcomes during the study period.  Women undergoing obstetrically indicated CS without labour in their first delivery may have reduced risks of pelvic floor health disorders, even after multiple deliveries. These findings contribute important information for health care providers when counselling women and their families who are weighing the risk of long term pelvic floor disorders against the benefits of spontaneous vaginal delivery.
Pelvic Floor Health Education: Can a Workshop Enhance Patient Counseling During Pregnancy?
Venue: Female pelvic medicine reconstructive surgery

Pelvic floor disorders commonly affect women's quality of life. Their etiology is multifactorial, yet pregnancy and vaginal delivery (VD) are major inciting risk factors. Our objectives were to assess pelvic floor health information given by maternity providers to their pregnant patients, to create a pelvic floor health information workshop, and to determine its impact on women's preferences for mode of delivery.  This descriptive study recruited primiparous women with a singleton gestation at St Paul's Hospital in Vancouver, Canada. Participants received a 2 hour workshop describing pelvic floor disorders and pregnancy, modes of delivery, as well as strategies for maintaining pelvic floor health and preventing disease. Women completed questionnaires assessing baseline knowledge and level of comfort with different modes of delivery before and after the workshop.  Forty participants completed the workshop. Seventy percent had an obstetrician, 20% had a midwife, and 10% had a family physician. Five percent of the participants reported receiving information regarding pelvic organ prolapse as well as urinary and fecal incontinence. The workshop did not influence women's preferred mode of delivery, including VD (P 1.00) forceps assisted VD (P 0.48) vacuum assisted VD (P 0.68) postlabor cesarean delivery (P 0.32) and elective cesarean delivery (P 0.86) Conclusions Current antenatal care is lacking in the area of pelvic floor health education. Patient counseling can be enhanced via a standard workshop. Concerns about negatively influencing women's preferences for mode of delivery are unwarranted, as the pelvic floor health workshop, given during pregnancy, did not significantly change participants' preferences.
Motivation in organizational behavior: History, advances and prospects

In this article we selectively review major advances in research on motivation in work and organizational behavior since the founding of Organizational Behavior and Human Performance (now Organizational Behavior and Human Decision Processes) 50years ago. Using a goal based organizing rubric, we highlight the most impactful articles and summarize research progress over time related to understanding the why, where, how, what, and when of motivation during goal choice and goal enactment. We also note macro level trends in motivation research published in this journal, including the shift away from publishing new, core theories of work motivation in favor of using new approaches published elsewhere to examine key micro regulatory processes involved in goal decisions and goal pursuit. We conclude with discussion of promising future research directions.
The WebNLG Challenge: Generating Text from DBPedia Data
Venue: INLG

With the emergence of the linked data initiative and the rapid development of RDF (Resource Description Format) datasets, several approaches have recently been proposed for generating text from RDF data (Sun and Mellish, 2006; Duma and Klein, 2013; Bontcheva and Wilks, 2004; Cimiano et al. 2013; Lebret et al. 2016) To support the evaluation and comparison of such systems, we propose a shared task on generating text from DBPedia data. The training data will consist of Data/Text pairs where the data is a set of triples extracted from DBPedia and the text is a verbalisation of these triples. In essence, the task consists in mapping data to text. Specific subtasks include sentence segmentation (how to chunk the input data into sentences) lexicalisation (of the DBPedia properties) aggregation (how to avoid repetitions) and surface realisation (how to build a syntactically correct and natural sounding text)
Non intrusive Monitoring of Stream Processing Applications
Venue: 2016 IEEE Symposium on Service Oriented System Engineering (SOSE)

Stream processing applications have emerged as a popular way for implementing high volume data processing tasks. In contrast to traditional data processing models that persist data to databases and then execute queries on the stored data, stream processing applications continuously execute complex queries on incoming data to produce timely results in reaction to events observed in the processed data. To cope with the request load, components of a stream processing application are usually distributed across multiple machines. In this context, performance monitoring and testing are naturally important for stakeholders to understand as well as analyze the runtime characteristics of deployed applications to identify issues and inform decisions. Existing approaches for monitoring the performance of distributed systems, however, do not provide sufficient support for targeted monitoring of stream processing applications, and require changes to the application code to enable the integration of application specific monitoring data. In this paper we present MOSAIC, a service oriented framework that allows for in depth analysis of stream processing applications by non intrusively adding functionality for acquiring and publishing performance measurements at runtime, to the application. Furthermore, MOSAIC provides a flexible mechanism for integrating different stream processing frameworks, which can be used for executing and monitoring applications independent from a specific operator model. Additionally, our framework provides an extensible approach for gathering and analyzing measurement data. In order to evaluate our solution, we developed a scenario application, which we used for testing and monitoring its performance on different stream processing engines.
A Cyborg Manifesto

This chapter is an effort to build an ironic political myth faithful to feminism, socialism, and materialism. Perhaps more faithful as blasphemy is faithful, than as reverent worship and identification. Blasphemy has always seemed to require taking things very seriously. I know no better stance to adopt from within the secular religious, evangelical traditions of United States politics, including the politics of socialist feminism. Blasphemy protects one from the moral majority within, while still insisting on the need for community. Blasphemy is not apostasy. Irony is about contradictions that do not resolve into larger wholes, even dialectically, about the tension of holding incompatible things together because both or all are necessary and true. Irony is about humour and serious play. It is also a rhetorical strategy and a political method, one I would like to see more honoured within socialist feminism. At the centre of my ironic faith, my blasphemy, is the image of the cyborg.
Modified rectifier circuit for high efficiency and low power RF energy harvester
Venue: 2016 13th International Multi Conference on Systems, Signals Devices (SSD)

In this work, a passive rectifier circuit is presented, which is operating at 868 MHz. It allows energy harvesting from low power RF waves with a high efficiency. It consists of a novel multiplier circuit design and high quality components to reduce parasitic effects, losses and reaches a low startup voltage. Using lower capacitor rises up the switching speed of the whole circuit. An inductor L serves to store energy in a magnetic field during the negative cycle wave and returns it during the positive one. A low pass filter is arranged in cascade with the rectifier circuit to reduce ripple at high frequencies and to get a stable DC signal. A 50 kO load is added at the output to measure the output power and to visualize the behavior of the whole circuit. Simulation results show an outstanding potential of this RF DC converter witch has a relative high sensitivity beginning with 40 dBm.